A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia

Study Identifier:

SEP361-121

ClinicalTrials.gov Identifier:

NCT05848700

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Study Complete

Subscribe to Updates

Study Details

Medical Condition

Schizophrenia

Study Drug

Drug: SEP-363856
Drug: Placebo

Date

Jun 2023 - Mar 2024

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 18 - 65 Years

Requirements Information

Protocol Summary

A Clinical Study to learn if SEP-363856 has physical dependence in adults with schizophrenia. This study will be held in approximately 6 study sites in the United States. It will be accepting male and female participants age 18 years to 65 years. Participation will be up to approximately10 weeks.

Study Locations

Location

Status

Location

Woodland International Research Group, LLC

Little Rock, Arkansas, United States, 72211

Status

N/A

Location

Woodland Research Northwest

Rogers, Arkansas, United States, 72758

Status

N/A

Location

Behavioral Clinical Research, Inc

Miami Lakes, Florida, United States, 33016

Status

N/A

Location

Research Centers of America at Fort Lauderdale Behavioral Health Center

Oakland Park, Florida, United States, 33334

Status

N/A

Location

Atlanta Center for Medical Research

Atlanta, Georgia, United States, 30331

Status

N/A

Location

Neuro-Behavioral Clinical Research, Inc

North Canton, Ohio, United States, 44720

Status

N/A